Amorsa Therapeutics, Inc. logo

Amorsa Therapeutics, Inc.

Amorsa is a preclinical stage, neuropharmaceutical company pioneering the development of improved treatments for nervous system disorders including treatment-resistant depression and moderate-to-severe pain.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.amorsatx.com
Founded2013
Disease Focus
Development StagePreclinical
STOCK CODENon Listed
Address
164 Cordaville Rd., Ste. 628 Southborough, MA 01772
Massachusetts
United States
Email
Contact Number
+1 508-571-8240

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/amo-pharma-limited” connections=”true” suffix=””]

Amorsa is developing a novel patent-protected sustained release oral formulation of the FDA approved anesthetic, ketamine, for use in refractory cancer pain.

Jan 2017, Amorsa collaborate with Johnson & Johnson Innovation to develop new therapy for treatment – Resistant Depression. Amorsa will receive an upfront payment, along with research funding, preclinical, clinical, regulatory and sales milestones, plus tiered royalties on product sales.